LIDDS Investor Relations Material
Latest events
Q1 2025
28 May, 2025
Q4 2024
20 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from LIDDS
Access all reports
LIDDS AB is a Swedish pharmaceutical company that focuses on drug delivery technologies, particularly for cancer treatment. Its proprietary technology, NanoZolid, enables localized and controlled release of drugs for up to six months, reducing systemic side effects. LIDDS leverages this platform to develop its own oncology-focused pipeline, which includes candidates such as Nanodotax (a NanoZolid-formulated chemotherapy) and Nanoimod (a TLR9 agonist for cancer immunotherapy). The company's strategy also involves partnering with other pharmaceutical firms to enhance drug efficacy and safety using its drug delivery technology. LIDDS is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
LIDDS
Country
🇸🇪 Sweden